Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 127Lung Neoplasms 51Triple Negative Breast Neoplasms 35Breast Neoplasms 34Small Cell Lung Carcinoma 30Ovarian Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Neoplasm Metastasis 21Fallopian Tube Neoplasms 20Endometrial Neoplasms 20Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 15Head and Neck Neoplasms 13Colorectal Neoplasms 11Carcinoma 11Prostatic Neoplasms 9Oropharyngeal Neoplasms 9Esophageal Neoplasms 9Urinary Bladder Neoplasms 8Carcinoma, Transitional Cell 8Pancreatic Neoplasms 7Carcinoma, Squamous Cell 7Lung Diseases 6Laryngeal Neoplasms 6Carcinoma, Ovarian Epithelial 6Adenocarcinoma of Lung 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Mouth Neoplasms 5Mesothelioma 5

Interventions

pembrolizumab 1osimertinib 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paroxetine 1Paclitaxel 1Itraconazole 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Carboplatin × 90 days × Clear all
NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡